UBS Group’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$18.4M Sell
212,800
-15,400
-7% -$1.48M ﹤0.01% 2682
2025
Q4
$21.9M Sell
228,200
-21,200
-9% -$2.06M ﹤0.01% 2506
2025
Q3
$23.8M Buy
249,400
+66,600
+36% +$6.12M ﹤0.01% 2374
2025
Q2
$15.9M Sell
182,800
-259,200
-59% -$22M ﹤0.01% 2618
2025
Q1
$39.7M Buy
442,000
+83,700
+23% +$7.49M 0.01% 1692
2024
Q4
$28.6M Buy
358,300
+74,000
+26% +$6.41M 0.01% 1959
2024
Q3
$25.6M Buy
284,300
+33,900
+14% +$2.85M 0.01% 1633
2024
Q2
$19.7M Buy
250,400
+68,200
+37% +$5.59M ﹤0.01% 1685
2024
Q1
$15.9M Buy
182,200
+91,800
+102% +$7.83M ﹤0.01% 1871
2023
Q4
$7.45M Buy
90,400
+39,700
+78% +$3.03M ﹤0.01% 2356
2023
Q3
$3.97M Buy
50,700
+300
+0.6% +$25.1K ﹤0.01% 2800
2023
Q2
$4.44M Sell
50,400
-205,100
-80% -$17.7M ﹤0.01% 2713
2023
Q1
$20.6M Sell
255,500
-69,700
-21% -$5.68M 0.01% 1366
2022
Q4
$25.3M Sell
325,200
-142,900
-31% -$11.6M 0.01% 1249
2022
Q3
$37.8M Buy
468,100
+107,200
+30% +$9.63M 0.02% 851
2022
Q2
$32.4M Sell
360,900
-19,300
-5% -$1.96M 0.01% 1020
2022
Q1
$42.2M Buy
380,200
+138,296
+57% +$14.6M 0.01% 948
2021
Q4
$25M Buy
241,904
+47,110
+24% +$5.46M 0.01% 1427
2021
Q3
$24.4M Sell
194,794
-49,100
-20% -$6.36M 0.01% 1347
2021
Q2
$30.3M Buy
243,894
+66,400
+37% +$8.34M 0.01% 1164
2021
Q1
$21M Sell
177,494
-306,006
-63% -$35.9M 0.01% 1417
2020
Q4
$56.6M Buy
483,500
+460,700
+2,021% +$50.7M 0.02% 730
2020
Q3
$2.37M Buy
22,800
+700
+3% +$70.3K ﹤0.01% 2894
2020
Q2
$2.03M Buy
22,100
+8,700
+65% +$834K ﹤0.01% 2868
2020
Q1
$1.21M Sell
13,400
-98,900
-88% -$10.5M ﹤0.01% 3197
2019
Q4
$12.7M Sell
112,300
-10,700
-9% -$1.17M ﹤0.01% 1726
2019
Q3
$13.4M Sell
123,000
-102,400
-45% -$10.7M 0.01% 1540
2019
Q2
$22M Buy
225,400
+200,200
+794% +$18.3M 0.01% 1152
2019
Q1
$2.29M Sell
25,200
-196,700
-89% -$17.6M ﹤0.01% 2876
2018
Q4
$20.2M Buy
221,900
+122,700
+124% +$11.5M 0.01% 1081
2018
Q3
$9.76M Buy
99,200
+3,900
+4% +$361K ﹤0.01% 1803
2018
Q2
$8.16M Sell
95,300
-25,200
-21% -$2.1M ﹤0.01% 1912
2018
Q1
$9.67M Sell
120,500
-331,000
-73% -$27.3M ﹤0.01% 1716
2017
Q4
$36.5M Buy
451,500
+318,700
+240% +$25.5M 0.02% 827
2017
Q3
$10.3M Buy
132,800
+70,500
+113% +$5.85M ﹤0.01% 1599
2017
Q2
$5.53M Sell
62,300
-4,600
-7% -$388K ﹤0.01% 2062
2017
Q1
$5.39M Sell
66,900
-57,211
-46% -$4.47M ﹤0.01% 2031
2016
Q4
$8.84M Sell
124,111
-14,486
-10% -$1.14M ﹤0.01% 1600
2016
Q3
$12M Buy
138,597
+29,311
+27% +$2.55M 0.01% 1293
2016
Q2
$9.48M Sell
109,286
-88,130
-45% -$7.13M 0.01% 1421
2016
Q1
$14.8M Buy
197,416
+176,216
+831% +$13.3M 0.01% 1074
2015
Q4
$1.63M Sell
21,200
-132,826
-86% -$10M ﹤0.01% 2997
2015
Q3
$10.3M Sell
154,026
-245,500
-61% -$18.1M 0.01% 1342
2015
Q2
$29.6M Buy
399,526
+248,226
+164% +$19M 0.02% 753
2015
Q1
$11.8M Sell
151,300
-1,881,619
-93% -$143M 0.01% 1341
2014
Q4
$147M Buy
+2,032,919
New +$141M 0.1% 211

Other funds holding MDT

UBS Group's MDT Position: Q1 2026 in Review

UBS Group increased its Medtronic (MDT) stake by 54% in Q1 2026, buying an estimated $215M and bringing the position to 6,412,252 shares worth $556M. The position accounts for 0.08% of the portfolio, ranked #245.

UBS Group first reported a position in MDT in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.7B in Q4 2019. 2,230 funds tracked by Wall St. Rank hold MDT as of Q1 2026.

  • UBS Group held 6,412,252 shares of Medtronic worth $556M as of Q1 2026.
  • UBS Group bought 2,241,365 Medtronic shares in Q1 2026, an estimated $215M.
  • Medtronic made up 0.08% of UBS Group's portfolio in Q1 2026, its #245 holding.
  • UBS Group first reported a position in Medtronic in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Medtronic position peaked at $1.7B in Q4 2019.
  • 2,230 funds tracked by Wall St. Rank held Medtronic as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.